CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
快速大剂量环磷酰胺作为多发性骨髓瘤高级治疗的桥接治疗
英文原题：Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
查看英文原题
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
接受嵌合抗原受体（CAR）T细胞疗法或双特异性抗体（BsAb）治疗的复发/难治性多发性骨髓瘤患者，可能需要桥接治疗以获得后续疗法获益。本研究评估15例计划接受CAR-T、BsAb或长期方案治疗的患者使用快速外周大剂量环磷酰胺（TurboCy）的疗效和安全性。在既往接受多线治疗的高危队列中，总体缓解率为80%，临床获益率为100%。血细胞减少较常见，但桥接期间未发生死亡。所有患者均顺利进入预定下一线治疗。TurboCy是一种有效且安全的桥接策略。
展开英文摘要原文
Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits.
We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.
论文信息
- 作者
- Marable M、Kelly K、Cooperrider JH、Jakubowiak A、Derman BA
- 单位
- Department of Medicine University of Chicago Chicago Illinois USA.United States
- 期刊
- EJHaem2024 Dec
- 原文标识
- PubMed 39691273 · DOI 10.1002/jha2.1039
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →